Comparative Pharmacology
Head-to-head clinical analysis: ANORO ELLIPTA versus BEVESPI AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANORO ELLIPTA versus BEVESPI AEROSPHERE.
ANORO ELLIPTA vs BEVESPI AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANORO ELLIPTA is a combination of umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation. Vilanterol stimulates beta2-adrenergic receptors, leading to relaxation of bronchial smooth muscle and increased cyclic AMP.
BEVESPI AEROSPHERE is a combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA). Glycopyrrolate inhibits acetylcholine at M3 muscarinic receptors in bronchial smooth muscle, leading to bronchodilation. Formoterol stimulates beta2-adrenergic receptors, increasing cyclic AMP and relaxing bronchial smooth muscle.
One inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily, orally inhaled.
Two inhalations (glycopyrrolate 18 mcg / formoterol fumarate 9.6 mcg per inhalation) twice daily, administered orally via inhalation.
None Documented
None Documented
Umeclidinium: 11 hours (terminal); vilanterol: 2.5 hours (terminal). Steady-state achieved by day 14 once-daily dosing.
Glycopyrrolate: terminal elimination half-life 3.2 to 4.1 hours after inhalation; formoterol: terminal elimination half-life approximately 10 hours after inhalation. Context: Steady-state achieved within 2 to 3 days.
Umeclidinium: 0.7% unchanged in urine, 58% as metabolites in feces; vilanterol: 26% unchanged in urine, 70% as metabolites in feces. Total elimination: renal (30-40% for vilanterol metabolites) and fecal (primary).
Renal: 15% to 30% as unchanged drug after intravenous administration for glycopyrrolate; fecal: 65% to 80% as unchanged drug after oral administration for glycopyrrolate. For formoterol, renal: 10% to 20% as unchanged drug; bile/fecal: 60% to 70%.
Category C
Category C
LAMA/LABA Combination
LAMA/LABA Combination